Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW642444H · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| GW642444M 25mcg | EXPERIMENTAL | Subject will inhale single dose of GW642444M 25 mcg via a DISKUS device in morning. |
| GW642444M 100mcg | EXPERIMENTAL | Subject will inhale single dose of GW642444M 100 mcg via a DISKUS device in morning. |
| GW642444M 400mcg | EXPERIMENTAL | Subject will inhale single dose of GW642444M 400 mcg via a DISKUS device in morning. |
| GW642444H 100mcg | EXPERIMENTAL | Subject will inhale single dose of GW642444H 100 mcg via a DISKUS device in morning. |
| placebo | PLACEBO_COMPARATOR | Subject will inhale single dose of Placebo via a DISKUS device in morning. |
| Name | Type | Description |
|---|---|---|
| GW642444H (100mcg) | DRUG | H salt |
| placebo | DRUG | placebo |
| GW642444M (25, 100 & 400 mcg) | DRUG | M salt |
Inclusion criteria: * male or female (of non-childbearing potential) between 18 - 70 years * History of stable mild to moderate asthma * non - smokers * currently taking daily doses of inhaled fluticasone propionate 200 - 500 mcg (or equivalent) * body weight \>50 kg with BMI 19-29.9 kg/m2 * normal...
GW642444H is an investigational small molecule being studied for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is administered via inhalation and is currently in Phase 1 clinical development. The drug is not yet approved and remains under investigation for respiratory conditions.
GW642444H is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for respiratory diseases.
GW642444H is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
GW642444H has one completed Phase 1 clinical trial registered under NCT00463697. This study investigated the effect of inhaling a single dose of GW642444M in asthmatic patients. The trial enrolled 20 participants in the United Kingdom and was a randomized, double-blind, placebo-controlled study.
GW642444H and GW642444M are related forms of the same investigational drug. The clinical trial NCT00463697 studied GW642444M, which is the active form administered via inhalation. GW642444H is the drug name used in development records, and both refer to the same compound under investigation.